lvrachЛечащий ВрачLechaschi Vrach1560-51752687-1181ООО «Издательство "Открытые системы"»lvrach-327Research ArticleСтатьиКоррекция метаболического профиля больных сахарным диабетом 2 типа, страдающих ожирением, антидиабетическим препаратом с активным компонентом на основMetabolic profile correction in patients with type 2 diabetes mellitus, suffering from obesity, with antidiabetic drug with active component based on the antibodies to C-terminal fragment of the β-subunit of the insulin receptorРоговаН. В.RogovaN. V.corfnv1709@hotmail.comРязановаА. Ю.RyazanovaA. Yu.noemail@neicon.ruФГБОУ ВО ВолгГМУ Минздрава РоссииRussian Federation201923062021087272Copyright © Рогова Н.В., Рязанова А.Ю., 20212021Рогова Н.В., Рязанова А.Ю.Rogova N.V., Ryazanova A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.lvrach.ru/jour/article/view/327

Всемирная организация здравоохранения называет ожирение и сахарный диабет 2 типа (СД 2 типа) замедленной катастрофой. Существует достоверная связь между сахарным диабетом и риском развития сердечно-сосудистых катастроф, возникновения онкологических заболеваний и нарушением когнитивных функций. Инсулинорезистентность рассматривается как одно из ключевых звеньев в развитии данных заболеваний. Соответственно, современные препараты для лечения СД 2 типа должны не только решать вопрос о нормализации параметров углеводного обмена, а также обладать плейотропными свойствами, воздействуя на патогенез. В данной статье рассматривается терапевтическое действие технологически обработанных антител к С-концевому фрагменту ?-субъединицы рецептора инсулина при лечении пациентов с СД 2 типа и ожирением.

The world health organization calls obesity and type 2 diabetes mellitus a delayed disaster. There is a significant relationship between diabetes mellitus and the risk of cardiovascular events, cancer and cognitive impairment. Insulin resistance is considered one of the key links in the development of these diseases. For this reason, modern antidiabetic drugs should not only solve the problem of normalization of carbohydrate metabolism parameters, but also have pleiotropic properties, affecting the pathogenesis. This article discusses the therapeutic effect of technologically processed antibodies to the C-terminal fragment of the β-subunit of the insulin receptor in the treatment of patients with type 2 diabetes mellitus and obesity. 

Антитела к С-концевому фрагменту b-субъединицы рецептора инсулинаКлинические исследованияОжирениеСахарный диабетТерапияУглеводный обменЭндокринологияdiabetes mellituscarbohydrate metabolismobesityantibodies to the C-terminal fragment of the β-subunit of the insulin receptorReferencesZheng Y., Ley S. H., Hu F. B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications // Nat Rev Endocrinol. 2018, Feb; 14 (2): 88-98.Zheng Y., Ley S. H., Hu F. B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications // Nat Rev Endocrinol. 2018, Feb; 14 (2): 88-98.WHO: Obesity and Overweight. Fact sheet No. 311. 2016. www.who.int/mediacentre/factsheets/fs311/en/ (доступно на 28.06.2019).WHO: Obesity and Overweight. Fact sheet No. 311. 2016. www.who.int/mediacentre/factsheets/fs311/en/ (доступно на 28.06.2019).Prospective Studies Collaboration, Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., Qizilbash N., Collins R., Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies // Lancet. 2009; 373: 1083-1096.Prospective Studies Collaboration, Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., Qizilbash N., Collins R., Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies // Lancet. 2009; 373: 1083-1096.Fried M., Yumuk V., Oppert J. M., Scopinaro N., Torres A. J., Weiner R., Yashkov Y., Fruhbeck G. European Association for the Study of Obesity, International Federation for the Surgery of Obesity - European Chapter: Interdisciplinary European guidelines on metabolic and bariatric surgery // Obes Facts. 2013; 6: 449-468.Fried M., Yumuk V., Oppert J. M., Scopinaro N., Torres A. J., Weiner R., Yashkov Y., Fruhbeck G. European Association for the Study of Obesity, International Federation for the Surgery of Obesity - European Chapter: Interdisciplinary European guidelines on metabolic and bariatric surgery // Obes Facts. 2013; 6: 449-468.International Diabetes Federation: Diabetes Atlas, 2nd ed. Brussels, International Diabetes Federation, 2003. www.diabetesatlas.org/component/attachments/?task=download&id=73 (доступно на 28.06.2019).International Diabetes Federation: Diabetes Atlas, 2nd ed. Brussels, International Diabetes Federation, 2003. www.diabetesatlas.org/component/attachments/?task=download&id=73 (доступно на 28.06.2019).Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world - a growing challenge // N Engl J Med. 2007; 356: 213-215.Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world - a growing challenge // N Engl J Med. 2007; 356: 213-215.Oldridge N. B., Stump T. E., Nothwehr F. K., Clark D. O. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults // J Clin Epidemiol. 2001; 54: 928-934.Oldridge N. B., Stump T. E., Nothwehr F. K., Clark D. O. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults // J Clin Epidemiol. 2001; 54: 928-934.Boucher J., Kleinridders A., Kahn R. C. Insulin Receptor Signaling in Normal and Insulin-Resistant // States Cold Spring Harb Perspect Biol. 2014; 6: a009191.Boucher J., Kleinridders A., Kahn R. C. Insulin Receptor Signaling in Normal and Insulin-Resistant // States Cold Spring Harb Perspect Biol. 2014; 6: a009191.Bays H., Mandarino L., DeFronzo R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach // J Clin Endocrinol Metab. 2004, Feb; 89 (2): 463-478.Bays H., Mandarino L., DeFronzo R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach // J Clin Endocrinol Metab. 2004, Feb; 89 (2): 463-478.Granberry M. C., Fonseca V. A. Insulin resistance syndrome: options for treatment // South Med J. 1999, Jan; 92 (1): 2-15.Granberry M. C., Fonseca V. A. Insulin resistance syndrome: options for treatment // South Med J. 1999, Jan; 92 (1): 2-15.Kasuga M., Karlsson F. A., Kahn C. R. Insulin stimulates the phosphorylation of the 95,000-Dalton subunit of its own receptor // Science. 1982, Feb, 215 (4529): 185-187.Kasuga M., Karlsson F. A., Kahn C. R. Insulin stimulates the phosphorylation of the 95,000-Dalton subunit of its own receptor // Science. 1982, Feb, 215 (4529): 185-187.Gual P., Baron R., Alengrin F., Mothe I., Obberghen E. Insulin Receptor-Induced Phosphorylation of Cellular and Synthetic Substrates Is Regulated bythe Receptor P-Subunit C-Terminus // Endocrinology. 1996. Vol. 137. P. 3416-3423.Gual P., Baron R., Alengrin F., Mothe I., Obberghen E. Insulin Receptor-Induced Phosphorylation of Cellular and Synthetic Substrates Is Regulated bythe Receptor P-Subunit C-Terminus // Endocrinology. 1996. Vol. 137. P. 3416-3423.Paz K., Voliovitch H., Hadari Y. R., Roberts C. T., LeRoith J. D., Zick Y. Interaction between the Insulin Receptor and Its Downstream Effectors // Journal of Biological Chemistry. 1996. Vol. 271. P. 6998-7003.Paz K., Voliovitch H., Hadari Y. R., Roberts C. T., LeRoith J. D., Zick Y. Interaction between the Insulin Receptor and Its Downstream Effectors // Journal of Biological Chemistry. 1996. Vol. 271. P. 6998-7003.Sykiotis G. P., Papavassiliou A. G. Serine Phosphorylation of Insulin Receptor Substrate-1: A Novel Target for the Reversal of Insulin Resistance // Molecular Endocrinology. 2001. Vol. 15 (11). P. 1864-1869.Sykiotis G. P., Papavassiliou A. G. Serine Phosphorylation of Insulin Receptor Substrate-1: A Novel Target for the Reversal of Insulin Resistance // Molecular Endocrinology. 2001. Vol. 15 (11). P. 1864-1869.Paz K., Hemi R., LeRoith D., Karasik A., Elhananyi E., Kanety H., Zick Y. A Molecular Basis for Insulin Resistance // Journal of Biological Chemistry. 1997. Vol. 272. P. 29911-29918.Paz K., Hemi R., LeRoith D., Karasik A., Elhananyi E., Kanety H., Zick Y. A Molecular Basis for Insulin Resistance // Journal of Biological Chemistry. 1997. Vol. 272. P. 29911-29918.Adel S. Al-Zubairi, Eltayeb Elamin M. Molecular Targets in the Development of Antidiabetic Drugs // International Journal of Pharmacology. 2010, 6: 784-795.Adel S. Al-Zubairi, Eltayeb Elamin M. Molecular Targets in the Development of Antidiabetic Drugs // International Journal of Pharmacology. 2010, 6: 784-795.Vaz J. A., Patnaik A. Diabetes mellitus: Exploring the challenges in the drug development process // Perspect Clin Res. 2012; 3 (3): 109-112.Vaz J. A., Patnaik A. Diabetes mellitus: Exploring the challenges in the drug development process // Perspect Clin Res. 2012; 3 (3): 109-112.Bornfeldt K. E., Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis // Cell Metab. 2011; 14 (5): 575-585.Bornfeldt K. E., Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis // Cell Metab. 2011; 14 (5): 575-585.Orgel E., Mittelman S. D. The links between insulin resistance, diabetes, and cancer // Curr Diab Rep. 2013; 13 (2): 213-222.Orgel E., Mittelman S. D. The links between insulin resistance, diabetes, and cancer // Curr Diab Rep. 2013; 13 (2): 213-222.Jia G., DeMarco V. G., Sowers J. R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy // Nat Rev Endocrinol. 2016; 12 (3): 144-153.Jia G., DeMarco V. G., Sowers J. R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy // Nat Rev Endocrinol. 2016; 12 (3): 144-153.Joost H. G., Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review) // Mol Membr Biol. 2001; 18 (4): 247-256.Joost H. G., Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review) // Mol Membr Biol. 2001; 18 (4): 247-256.Горбунов Е. А., Nicoll J., Мысливец А. А. и др. Субетта повышает чувствительность мышечных клеток человека к инсулину // Бюллетень экспериментальной биологии и медицины. 2015; 159 (4): 454-456.Горбунов Е. А., Nicoll J., Мысливец А. А. и др. Субетта повышает чувствительность мышечных клеток человека к инсулину // Бюллетень экспериментальной биологии и медицины. 2015; 159 (4): 454-456.Yazici D., Sezer H. Insulin Resistance, Obesity and Lipotoxicity // Adv Exp Med Biol. 2017; 960: 277-304.Yazici D., Sezer H. Insulin Resistance, Obesity and Lipotoxicity // Adv Exp Med Biol. 2017; 960: 277-304.Nicoll J., Gorbunov E. A., Tarasov S. A., Epstein O. I. Subetta Treatment Increases Adiponectin Secretion by Mature Human Adipocytes In Vitro // International Journal of Endocrinology. 2013: 925874. Published online 2013, Apr 18.Nicoll J., Gorbunov E. A., Tarasov S. A., Epstein O. I. Subetta Treatment Increases Adiponectin Secretion by Mature Human Adipocytes In Vitro // International Journal of Endocrinology. 2013: 925874. Published online 2013, Apr 18.Gorbunov E. А., Nicoll J., Kachaeva E. V., Tarasov S. А., Epstein О. I. Subetta increases phosphorylation of insulin receptor ?-subunit alone and in the presence of insulin // Nutrition & Diabetes. 2015. Vol. 5 (7). P. 169.Gorbunov E. А., Nicoll J., Kachaeva E. V., Tarasov S. А., Epstein О. I. Subetta increases phosphorylation of insulin receptor ?-subunit alone and in the presence of insulin // Nutrition & Diabetes. 2015. Vol. 5 (7). P. 169.Инструкция по медицинскому применению препарата Субетта. ЛСР - 007376/10 grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 83f9a6c1-1115-41a2-b329-440652c7954e&t. Доступно на 28.06.2019.Инструкция по медицинскому применению препарата Субетта. ЛСР - 007376/10 grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 83f9a6c1-1115-41a2-b329-440652c7954e&t. Доступно на 28.06.2019.

The authors declare that there are no conflicts of interest present.